Tro Kalayjian
Tro Kalayjian
Stop FollowingTro Kalayjian
View as an RSS Feed
- Depomed Plunges After Serada Results: Still An Attractive Buying Opportunity
- Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff
- Strategies and Outlook for Xenoport's Upcoming FDA PDUFA Date
- Despite Abbott Parting With Gralise, Depomed's Future Looks Bright
- Pharmaceutical Companies Reformulate Pain Products: How Investors Can Benefit
- Bionovo Completes Financing, Announces Plan of Action: Is the Worst Over?
-
FDA Setbacks Make Vivus a Buying Opportunity
- Depomed: Attractive and Under-Appreciated Potential
- Depomed's Stock Price Is a Gift Following FDA Approval of Pain Drug
- Sales Potential and Chances of FDA Approval for DepoMed's DM-1796
- Finding Opportunity in Abbott - Depomed Dispute
- News Stories Miss the Point as Depomed Approaches FDA Target Date
- Investment Opportunities in Women's Health
- Bionovo: Challenges Ahead, But Poised to Move Higher
- Serada Half Price Sale: DepoMed's Stock Price Poised to Climb
- Women's Health: After WHI, What's the Potential Market Size?
- Tylenol Ban Will Hurt Several Drug Manufacturers' Bottom Lines
- Santarus: Business Fundamentals Are Unchanged
- DepoMed: Protected by Cash and Headed Higher
